Welcome to our dedicated page for Waldencast news (Ticker: WALD), a resource for investors and traders seeking the latest updates and insights on Waldencast stock.
Waldencast plc operates as a global multi-brand beauty and wellness platform built around Obagi Medical and Milk Makeup. News about WALD commonly covers brand-level product launches, physician-dispensed skincare, cosmetics, suncare, and aesthetic offerings, including Obagi's advanced skincare products and Obagi® saypha® MagIQ™ hyaluronic acid filler.
Company updates also include quarterly and annual financial results, segment performance, channel and distribution developments, clinical-evidence collaborations for aesthetic products, supply-chain and credit-facility actions, and governance or reporting matters tied to financial restatements, internal control over financial reporting, and regulatory review.
Summary not available.
Waldencast (NASDAQ: WALD) announced it will file a Form 12b-25 with the SEC for a 15-day extension to submit its Annual Report for the fiscal year ending December 31, 2022. This delay stems from an ongoing review of year-end financial statements, particularly regarding accounting issues related to the sale of Obagi products in Vietnam. The Audit Committee is conducting an independent review to determine necessary adjustments. Additionally, Waldencast completed a 60% acquisition of its Southeast Asia distributor, clearing some accounts receivable while retaining rights to future payments. The company is also assessing internal accounting controls, facing potential challenges with the Annual Report's filing and lender engagements due to the ongoing review.
Waldencast has announced a binding letter of intent to acquire a 60% controlling interest in a newly formed entity from its Southeast Asia distributor. This acquisition targets the rapidly growing $11 billion skincare market in Southeast Asia, with the Obagi brand expected to experience accelerated growth. The deal is contingent upon due diligence and definitive agreements, with completion anticipated in the coming weeks. Additionally, Waldencast has rescheduled its fourth quarter fiscal 2022 earnings call to April 26, 2023, to assess potential adjustments in financials relating to the acquisition.
Waldencast plc (NASDAQ: WALD) announced a conference call to discuss its fourth quarter 2022 earnings results, scheduled for March 15, 2023, at 8:30 AM ET. The earnings press release will be available before the call. Investors can join the call by dialing toll-free numbers or via a live webcast accessible on Waldencast's investor relations website. The company aims to establish a leading beauty and wellness platform, leveraging its brand-led business model and operational scale to enhance brand performance and customer engagement. More details can be found on their official website.
Waldencast, a global beauty and wellness platform (NASDAQ: WALD), announced its participation in key consumer conferences in March 2023. The Company will present at the Raymond James 44th Annual Institutional Investors Conference on March 6 at 1:05 p.m. EST in Orlando, Florida, and at the D.A. Davidson 6th Annual Consumer Conference on March 21 at 11:45 a.m. EST in New York City. CEO Michel Brousset will lead both events, which will be webcast and available for replay. Waldencast aims to develop and scale purpose-driven beauty brands, following its recent combination with Obagi Skincare and Milk Makeup.
Waldencast plc (NASDAQ: WALD) announced its participation in the 25th Annual ICR Conference on January 9, 2023, at 10:30 a.m. EST. CEO Michel Brousset will partake in a fireside chat, available live and on replay via the company's Investor Relations page. The firm aims to establish a leading global beauty and wellness platform through the development and scaling of purpose-driven brands.
Waldencast plc (NASDAQ: WALD) reported Q3 2022 net sales of $78.9 million with a gross margin of 62.4% and an adjusted gross margin of 71.9%. Despite these positive metrics, the company faced a net loss of $16.8 million. Adjusted EBITDA stood at $15.3 million, accounting for 19.4% of net sales. The management reaffirmed its fiscal 2022 guidance, projecting net sales of $256.3 million alongside a gross profit of $189.8 million and adjusted EBITDA of $49.6 million. Waldencast highlighted its robust brand performance and strong growth prospects in a challenging macroeconomic environment.
Waldencast plc (NASDAQ: WALD) is set to discuss its Q3 2022 earnings results on a conference call scheduled for November 10, 2022, at 8:30 AM ET. The earnings press release will be available before the call. Investors can join via phone or access a live webcast through their investor relations page. Waldencast aims to build a leading beauty and wellness platform by developing and scaling high-growth brands, benefiting from operational scale and market responsiveness.
Waldencast plc (NASDAQ: WALD) announced the appointment of Philippe Gautier as Chief Financial Officer and Chief Operating Officer, effective October 19, 2022. Gautier brings over 30 years of experience from leading global consumer companies, most recently as Group CFO at Selecta. His track record includes significant roles at Kering, managing luxury brands. CEO Michel Brousset expressed confidence that Gautier's expertise will enhance Waldencast's strategic goals in building a world-class beauty and wellness brand portfolio. The company aims to develop, acquire, and scale high-growth brands in this sector.
Waldencast plc (NASDAQ: WALD) will participate in the Raymond James 2022 Consumer Conference in New York on September 15, 2022, where CEO Michel Brousset will engage in a fireside chat. The session will be available for live viewing and replay on the company's Investor Relations page. Waldencast aims to build a leading beauty and wellness platform by developing and scaling purpose-driven brands, with its initial focus on Obagi Skincare and Milk Makeup. The company emphasizes agility and close customer connections, ensuring each brand retains its unique identity.